Systems and methods for rheumatoid arthritis biomarker detection

A method of detecting a first biomarker and at least a second biomarker associated with rheumatic disease in a biological sample of a subject, comprising:

• obtaining the biological sample from the subject;
• applying the biological sample to a lateral flow device under conditions sufficient for formation of a first immunocomplex comprising at least the first biomarker and a first labeled biomolecule capable of recognizing the first biomarker, and a second immunocomplex comprising at least the second biomarker and a second labeled biomolecule capable of recognizing the second biomarker, wherein the first biomarker is anti-citrullinated human serum albumin (HSA) autoantibody and wherein the second biomarker is one of rheumatoid factor (RF) or anti-citrullinated peptide autoantibody (ACAP);
• detecting a quantity of each of the first immunocomplex and the second immunocomplex;
• and
• managing rheumatic disease associated with the subject.

A lateral flow device capable of reporting a level of anti-citrullinated human serum albumin (HSA) autoantibodies in a biological sample obtained from a subject, the device comprising:

• a sample pad for receiving the biological sample;
• a conjugate pad that includes an anti-human serum albumin (HSA) antibody coupled to a first detectable label and a first control biomolecule coupled to a second detectable label;
• and
• a capture pad that includes a test line and a control line, the test line including one or more immobilized biomolecules capable of recognizing the anti-citrullinated HSA autoantibodies, and the control line including a second control biomolecule capable of binding the first control biomolecule.